Anti-CD4 antibodies have also shown benefit in non-hematologic malignancies via depletion of anti-inflammatory CD4 T cell subsets including Tregs, thereby allowing for enhanced proliferation of anti-tumor CD8 cytotoxic T cells (119). This evidence concerns the gene CD8A and neoplasm.